ArticleMetabolic brain disease2025
Protective effects of Fraxinus Micrantha against thioacetamide-induced hepatic encephalopathy: a focus on antioxidant and neuroprotective mechanisms.
Article in Metabolic brain disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatic encephalopathy (HE) is a multifaceted neuropsychiatric syndrome frequently observed in patients with liver dysfunction. The present study aimed to evaluate the therapeutic effects of Fraxinus micrantha (F. micrantha) in thioacetamide (TAA)-induced HE model. HE was induced using TAA (200 mg/kg i.p.) for once every 48 h for 14 consecutive days in rats. Ethyl acetate fraction of F. micrantha (EAFM) (50, 100, and 200 mg/kg) was administered for 14 consecutive days (p.o.) after HE induction. TAA induced hepatotoxicity and HE, evidenced by significant alterations in liver biomarkers alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP), lipid profiles (triglycerides, cholesterol), and neurotransmitter levels (serotonin, acetylcholine, dopamine, norepinephrine). Histopathological analysis revealed severe liver necrosis, inflammation, and brain damage, characterized by reduced neuronal density and hippocampal degeneration. EAFM treatment produced a significant, dose-dependent amelioration of TAA-induced liver injury, evidenced by the normalization of serum biomarkers (ALT, AST, ALP) and lipid profiles (cholesterol, triglycerides), with the 200 mg/kg dose showing efficacy comparable to silymarin. EAFM also exerted potent neuroprotective effects, restoring the altered levels of key neurotransmitters (serotonin, dopamine, norepinephrine) and reducing elevated acetylcholinesterase activity in the brain cortex and hippocampus. Furthermore, EAFM significantly mitigated oxidative stress by replenishing depleted reduced glutathione (GSH) levels in both hepatic and brain tissues. Histopathological analysis confirmed these findings, demonstrating that EAFM attenuated TAA-induced hepatocellular necrosis, inflammation, and hippocampal neurodegeneration. The results indicate that F. micrantha confers robust hepatoprotective and neuroprotective effects against HE, primarily mediated through its antioxidant activity and restoration of neurochemical balance, positioning it as a promising therapeutic candidate.
Indexed as
Identifiers
41045427What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.